Patents by Inventor Wensheng Yu

Wensheng Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection
    Patent number: 11976069
    Abstract: The present invention relates to Compounds of Formula I and Ia and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, X, A and B are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula I or Ia, and methods of using the compounds of Formula I or Ia for treating or preventing HIV infection in a subject.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: May 7, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Wensheng Yu, Joseph A. Kozlowski, Dane James Clausen, Jian Liu, James Fells
  • NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS
    Publication number: 20230008022
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: November 25, 2019
    Publication date: January 12, 2023
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Dane Clausen, Ping Chen, Xavier Fradera, Liangqin Guo, Yongxin Han, Shuwen He, Xianhai Huang, Joseph Kozlowski, Guoqing Li, Theodore A. Martinot, Alexander Pasternak, Andreas Verras, Li Xiao, Feng Ye, Wensheng Yu, Rui Zhang
  • Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
    Patent number: 11498904
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: November 15, 2022
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Yongxin Han, Abdelghani Achab, Indu Bharathan, Xavier Fradera, Derun Li, Nunzio Sciammetta, Wensheng Yu
  • NOVEL SUBSTITUTED TETRAHYDROQUINOLIN COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS
    Publication number: 20220235028
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: June 8, 2020
    Publication date: July 28, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Yongxin Han, Yongqi Deng, Hua Zhou, Meredeth A. McGowan, Hongjun Zhang, Wensheng Yu, Brett A. Hopkins, Xavier Fradera, Nunzio Sciammetta
  • INHIBITORS OF HISTONE DEACETYLASE-3 USEFUL FOR THE TREATMENT OF CANCER, INFLAMMATION, NEURODEGENERATION DISEASES AND DIABETES
    Publication number: 20220177465
    Abstract: The present invention relates to Compounds of Formula I: and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, R3, A and B are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treating or preventing cancer, inflammation, neurodegeneration disease and/or diabetes in a subject.
    Type: Application
    Filed: March 30, 2020
    Publication date: June 9, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jian LIU, Younong YU, Joseph A. KOZLOWSKI, Deyou SHA, Wensheng YU, Joseph M. KELLY, Scott E. WOLKENBERG
  • INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION
    Publication number: 20220144837
    Abstract: The present invention relates to Compounds of Formula I and Ia and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, X, A and B are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula I or Ia, and methods of using the compounds of Formula I or Ia for treating or preventing HIV infection in a subject.
    Type: Application
    Filed: March 16, 2020
    Publication date: May 12, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Wensheng Yu, Joseph A. Kozlowski, Dane James Clausen, Jian Liu, James Fells
  • Substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
    Patent number: 11319283
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (Formula (I)). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: May 3, 2022
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Meredeth Ann McGowan, Abdelghani Achab, Xavier Fradera, Yongxin Han, Derun Li, Jongwon Lim, Kun Liu, Nunzio Sciammetta, Catherine M. White, Wensheng Yu, Hongjun Zhang, Hua Zhou
  • INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION
    Publication number: 20210403479
    Abstract: The present invention relates to Compounds of Formula I: and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, R3, R4 and A are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treating or preventing HIV infection in a subject.
    Type: Application
    Filed: November 4, 2019
    Publication date: December 30, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Wensheng Yu, Joseph Kozlowski, Dane James Clausen, Jian Liu, Younong Yu, Ming Wang, Bing Li
  • Substituted phenyl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
    Patent number: 11208407
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (I) Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: December 28, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Hua Zhou, Abdelghani Achab, Xavier Fradera, Yongxin Han, Derun Li, Meredeth A. McGowan, Nunzio Sciammetta, David L. Sloman, Wensheng Yu
  • NOVEL SUBSTITUTED PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS
    Publication number: 20210395240
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: October 28, 2019
    Publication date: December 23, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Dane Clausen, Xavier Fradera, Liangqin Guo, Yongxin Han, Shuwen He, Joseph Kozlowski, Guoqing Li, Theodore A. Martinot, Alexander Pasternak, David Sloman, Li Xiao, Wensheng Yu, Rui Zhang
  • NOVEL ARYLALKYL PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS
    Publication number: 20210380572
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: October 11, 2019
    Publication date: December 9, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Dane Clausen, Ping Chen, Xavier Fradera, Liangqin Guo, Yongxin Han, Shuwen He, Jongwon Lim, Theodore A. Martinot, Alexander Pasternak, Li Xiao, Wensheng Yu
  • NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS
    Publication number: 20210330676
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: August 16, 2019
    Publication date: October 28, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Dane Clausen, Xavier Fradera, Liangqin Guo, Yongxin Han, Shuwen He, Xianhai Huang, Joseph Kozlowski, Guoqing Li, Jongwon Lim, Theodore A. Martinot, Alexander Pasternak, Nunzio Sciammetta, Andreas Verras, Li Xiao, Wensheng Yu, Rui Zhang
  • NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS
    Publication number: 20210317091
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an 1DO-associated disease or disorder.
    Type: Application
    Filed: November 9, 2018
    Publication date: October 14, 2021
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Yongxin Han, Abdelghani Achab, Indu Bharathan, Xavier Fradera, Derun Li, Nunzio Sciammetta, Wensheng Yu
  • INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION
    Publication number: 20210276992
    Abstract: The present invention relates to Compounds of Formula (I): Formula (I) and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, R3, Ra, Rb, A and B are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula (I), and methods of using the compounds of Formula (I) for treating or preventing HIV infection in a subject.
    Type: Application
    Filed: July 26, 2019
    Publication date: September 9, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jian Liu, Dane James Clausen, Wensheng Yu, Joseph M. Kelly, Hyunjin M. Kim, Joseph A. Kozlowski
  • Substituted cyclobutylpyridine and cyclobutylpyrimidine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
    Patent number: 11111232
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: September 7, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Catherine M. White, Abdelghani Achab, Indu T. Bharathan, Xavier Fradera, Yongxin Han, Derun Li, Jongwon Lim, Kun Liu, Meredeth Ann McGowan, Nunzio Sciammetta, Wensheng Yu, Hongjun Zhang, Hua Zhou
  • Substituted pyridinyl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
    Patent number: 11103493
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: August 31, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Hua Zhou, Xavier Fradera, Yongxin Han, Meredeth A. McGowan, Nunzio Sciammetta, Catherine White, Wensheng Yu
  • NOVEL SUBSTITUTED TETRAHYDROQUINOLIN COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS
    Publication number: 20210179607
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: October 29, 2018
    Publication date: June 17, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Yongqi Deng, Abdelghani Achab, Bridget A. Becker, David Jonathan Bennett, Indu Bharathan, Xavier Fradera, Craig Gibeau, Yongxin Han, Derun Li, Kun Liu, Qinglin Pu, Sulagna Sanyal, David Sloman, Wensheng Yu, Hongjun Zhang
  • Substituted N?-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase IDO inhibitors
    Patent number: 11034661
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: June 15, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Liangqin Guo, Yongxin Han, Kun Liu, Shuwen He, Joseph Kozlowski, Ravi Nargund, Wensheng Yu, Hongjun Zhang, Qinglin Pu, Derun Li, Abdelghani Achab, Guoqing Li
  • Substituted n?-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
    Patent number: 10988487
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: April 27, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kun Liu, Abdelghani Achab, Purakkattle Biju, Timothy A. Cernak, Yongqi Deng, Xavier Fradera, Liangqin Guo, Yongxin Han, Shuwen He, Joseph Kozlowski, Derun Li, Guoqing Li, Qinglin Pu, Zhi-Cai Shi, Wensheng Yu, Hongjun Zhang
  • Substituted sulfoximine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
    Patent number: 10927086
    Abstract: Compounds of Formula I, or a pharmaceutically acceptable salt, solvate or hydrate thereof: (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: February 19, 2018
    Date of Patent: February 23, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kun Liu, Dane Clausen, Liangqin Guo, Yongxin Han, Shuwen He, Joseph Kozlowski, Derun Li, Qinglin Pu, Wensheng Yu, Hongjun Zhang